Rebastinib (Genea Biocells)

N/A

Report date: 2025/03/17 10:04:31
NME

Base Information

Drug NameRebastinib (Genea Biocells)
Drug Alias NameRebastinibGBC-0905
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDouble homeobox protein 4 inhibitors
TargetsDouble homeobox protein 4
Therapy Area/IndicationsMuscular Dystrophy, Facioscapulohumeral
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenea Biocells US Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenea Biocells US Inc
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Facioscapulohumeral
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A